Evolus, Inc. (EOLS)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1570562 · fiscal year ends in Dec
Closing price $7.50 on 29 Oct 2026; 52-week range $3.94 to $9.30.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $316.5M
- Revenue growth
- 13.9%
- Net income, last twelve months
- -$34.3M
- Earnings per share
- -$0.52
- Gross margin
- 66.7%
- Operating margin
- -5.9%
- Net margin
- -10.8%
- Free cash flow
- -$18.3M
- Market value
- $495.4M
- Cash
- $45.2M
- Debt
- $156.7M
- Shares outstanding
- 66.0M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $297.2M | -$32.7M | -$51.6M | -$0.80 | -$45.7M | 10-K filed 3 Mar 2026 |
| FY2024 | 31 Dec 2024 | $266.3M | -$34.4M | -$50.4M | -$0.81 | -$19.5M | 10-K filed 4 Mar 2025 |
| FY2023 | 31 Dec 2023 | $202.1M | -$49.2M | -$61.7M | -$1.08 | -$34.5M | 10-K filed 7 Mar 2024 |
| FY2022 | 31 Dec 2022 | $148.6M | -$65.3M | -$74.4M | -$1.33 | -$86.5M | 10-K filed 8 Mar 2023 |
| FY2021 | 31 Dec 2021 | $99.7M | -$44.4M | -$46.8M | -$0.94 | -$33.8M | 10-K filed 3 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $84.1M | -$8.1M | -$0.12 |
| Q1 FY2026 | 31 Mar 2026 | $73.1M | -$10.7M | -$0.16 |
| Q4 FY2025 | 31 Dec 2025 | $90.3M | $130.0K | $0.00 |
| Q3 FY2025 | 30 Sep 2025 | $69.0M | -$15.7M | -$0.24 |
| Q2 FY2025 | 30 Jun 2025 | $69.4M | -$17.1M | -$0.27 |
| Q1 FY2025 | 31 Mar 2025 | $68.5M | -$18.9M | -$0.30 |
| Q4 FY2024 | 31 Dec 2024 | $78.9M | -$6.8M | -$0.11 |
| Q3 FY2024 | 30 Sep 2024 | $61.1M | -$19.2M | -$0.30 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Product revenue, net | $295.0M | 99.3% |
| Service revenue | $2.2M | 0.7% |
Company events
The newest 8-K filings of 99 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 5 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 4 Aug 2026 | 8-K | Material agreement, Investor update | 1.01, 7.01, 9.01 |
| 8 Jul 2026 | 8-K | Material agreement, Investor update | 1.01, 7.01, 9.01 |
| 12 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 4 May 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 13 Mar 2026 | 8-K | Leadership change | 5.02 |
| 3 Mar 2026 | 8-K | Results, Material agreement, New debt | 1.01, 2.02, 2.03, 9.01 |
| 9 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 5 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 8 Sep 2025 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 5 Aug 2025 | 8-K | Results, Leadership change | 2.02, 5.02, 9.01 |
| 6 Jun 2025 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07 |
Every filing
The newest filings with the SEC of 224 held.
| Filed | Form | Period |
|---|---|---|
| 5 Aug 2026 | 10-Q | 30 Jun 2026 |
| 5 Aug 2026 | 8-K | 5 Aug 2026 |
| 4 Aug 2026 | 8-K | 3 Aug 2026 |
| 8 Jul 2026 | 8-K | 7 Jul 2026 |
| 12 Jun 2026 | EFFECT | – |
| 12 Jun 2026 | 8-K | 11 Jun 2026 |
| 10 Jun 2026 | CORRESP | – |
| 10 Jun 2026 | UPLOAD | – |
| 5 Jun 2026 | S-3 | – |
| 4 May 2026 | 10-Q | 31 Mar 2026 |
| 4 May 2026 | 8-K | 4 May 2026 |
| 29 Apr 2026 | DEFA14A | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 2 Sep 2026 | Moatazedi David, See Remarks | Sale outside a trading plan | 105,108 | $9.04 | $950.0K | 499,592 | 4 Sep 2026 |
| 20 Mar 2026 | Avelar Rui, See Remarks | Sale outside a trading plan | 3,119 | $4.75 | $14.8K | 427,423 | 20 Mar 2026 |
| 20 Mar 2026 | Moatazedi David, See Remarks | Sale under a trading plan | 13,669 | $4.75 | $64.9K | 604,700 | 20 Mar 2026 |
| 17 Mar 2026 | Moatazedi David, See Remarks | Sale under a trading plan | 116,720 | $4.89 | $570.6K | 618,369 | 18 Mar 2026 |
| 17 Mar 2026 | Avelar Rui, See Remarks | Sale under a trading plan | 29,996 | $4.89 | $146.6K | 430,542 | 18 Mar 2026 |
| 22 Dec 2025 | Moatazedi David, See Remarks | Sale under a trading plan | 10,539 | $7.15 | $75.4K | 354,388 | 29 Dec 2025 |
| 22 Dec 2025 | Avelar Rui, See Remarks | Sale under a trading plan | 2,261 | $7.15 | $16.2K | 356,821 | 29 Dec 2025 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 2 Sep 2026 | DAVID MOATAZEDI, Officer, Director | 105,108 | $950.0K | 2 Sep 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 31 Aug 2026 | Soleus Capital Master Fund, L.P. | 13G | 5.3% | 3.5M |
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 17 Feb 2026 | Caligan Partners LP | 13G amended | 0% | 0 |
| 17 Feb 2026 | TANG CAPITAL MANAGEMENT, LLC | 13G amended | 1.92% | 1.2M |
| 17 Feb 2026 | Timothy P. Lynch | 13G amended | 9.9% | 6.4M |
| 14 Nov 2025 | Nantahala Capital Management, LLC | 13G amended | 8.85% | 5.7M |
| 14 Nov 2025 | Timothy P. Lynch | 13G amended | 7.9% | 5.1M |
| 14 Nov 2025 | Caligan Partners LP | 13G amended | 6.4% | 4.1M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 6.4M | +13.87% | 7.07 |
| 30 Sep 2026 | 5.6M | +1.76% | 9.33 |
| 15 Sep 2026 | 5.5M | +3.01% | 6.6 |
| 31 Aug 2026 | 5.4M | -8.28% | 5.21 |
| 14 Aug 2026 | 5.9M | +5.12% | 4.37 |
| 31 Jul 2026 | 5.6M | -5.72% | 8.74 |
| 15 Jul 2026 | 5.9M | -1.86% | 7.33 |
| 30 Jun 2026 | 6.0M | +2.09% | 7.3 |
Funds that hold it
From each fund's latest Form 13F.
178 funds held it at 30 Jun 2026: 85 added and 38 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Nantahala Capital Management, LLC | 11,204,042 | $77.8M | – |
| BlackRock, Inc. | 4,840,828 | $33.6M | +550,445 |
| Braidwell LP | 3,155,209 | $21.9M | +50,000 |
| Frazier Life Sciences Management, L.P. | 2,630,665 | $18.3M | 0 |
| Perceptive Advisors LLC | 2,459,285 | $17.1M | +1,172,423 |
| Vanguard Capital Management LLC | 2,362,893 | $16.4M | -107,515 |
| Assenagon Asset Management S.A. | 1,816,360 | $12.6M | – |
| Millennium Management LLC | 1,787,929 | $12.4M | +326,770 |
| State Street Corp. | 1,697,294 | $11.8M | +376,504 |
| Geode Capital Management, LLC | 1,608,394 | $11.2M | +227,056 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B